Compare Southern Copper Corp (SCCO) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Southern Copper Corp vs TG Therapeutics Inc — how do they compare? Southern Copper Corp trades at $209 (market cap $176.10B), while TG Therapeutics Inc trades at $54.77 (market cap $8.53B). The key difference: Southern Copper Corp is far larger — about 20.6× TG Therapeutics Inc's market cap, and Southern Copper Corp pays a 2.11% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SCCO | TGTX | |
|---|---|---|
Market Cap | $176.10B | $8.53B |
Sector | Basic Materials | Health |
52-Week High | $219.70 | $59.06 |
52-Week Low | $102.10 | $26.94 |
Enterprise Value | $177.39B | $8.74B |
Dividend Yield | 2.11% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Southern Copper (SCCO) trades at $208.56, up 4.93% with strong bullish technical signals and positive earnings momentum. The company demonstrates robust fundamentals with 2025 revenue of $13.42B, net income margin of 35.87%, and consistent earnings beats. Recent news highlights copper's role in AI infrastructure demand, with SCCO benefiting from rising metal prices and a $20.5B investment plan for production growth.
SCCO presents growth potential from copper demand trends but trades at premium valuations (P/E 31.29) above analyst consensus target of $154.58. Key risks include production declines and execution challenges on expansion projects. Institutional buying activity suggests confidence in long-term prospects despite mixed analyst ratings.
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Southern Copper Corp
Southern Copper Corp is an integrated producer of copper and other minerals and operates the mining, smelting, and refining facilities in Peru and Mexico. Its production includes copper, molybdenum, zinc, and silver. The company operates through the following segments: Peruvian operations, Mexican open-pit operations, and Mexican underground mining operations. Southern Copper generates the majority of its revenue from the sale of copper and the rest from the sale of non-copper products, such as molybdenum, silver, zinc, lead, and gold. Its geographical segments are The Americas, Europe, and Asia.
Read more on SCCO →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
